OTTAVA (J&J MedTech) vs PrecisionOS
Both carry FDA records of different kinds. OTTAVA holds a De Novo authorization from July 2026 (DEN250068, applicant Auris Health) for gastric bypass, gastrectomy, cholecystectomy, appendectomy and hiatal hernia repair among others. PrecisionOS holds a 510(k), K210344 decided in November 2021, that covers its inVisionOS planning tool and leaves the training library outside it.
Price sorts the buyers further. PrecisionOS charges $199 per month or $1,999 per year per individual, while OTTAVA is a capital sale with no public price.
These products do not compete. PrecisionOS is for an orthopedic residency director who wants VR cases in sports arthroscopy, shoulder, trauma, spine, foot and ankle and arthroplasty, an AI Attending mentor, and ACGME-aligned program reporting. OTTAVA is for a hospital OR director adding a soft-tissue robot, and its launch is limited to select US customers. Pain medicine and dental surgery cases are listed by PrecisionOS as coming.
Surgical AI · Reviewed November 1, 2026
OTTAVA (J&J MedTech)
by J&J MedTech
OTTAVA, Johnson & Johnson MedTech's soft-tissue surgical robot (FDA De Novo, July 2026), with its Polyphonic digital layer.
PrecisionOS
by PrecisionOS Technology
VR surgical training library for orthopedics and podiatry, plus inVisionOS, a patient-specific VR planning tool with an FDA 510(k) clearance.
When to pick each one
OTTAVA (J&J MedTech)
- FDA De Novo authorized, ten general surgery procedures
- Table-integrated robot, launched to select customers
- Polyphonic learning and data layer
PrecisionOS
- Individual plans $199 per month or $1,999 per year
- Orthopedics and podiatry VR case library
- FDA 510(k) covers the inVisionOS planning tool only
Score
Each row shows points earned of points available under the published rubric.
OTTAVA (J&J MedTech)
35of 100
PrecisionOS
59of 100
| Dimension | OTTAVA (J&J MedTech) | PrecisionOS | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 1.4 | 0 / 1.4 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 0.8 | 0 / 0.8 | 0 |
| Peer-reviewed papers | 0 / 21 | 14.7 / 21 | -14.7 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 7.8 / 7.8 | -7.8 |
| Funding & adoption signal | 8.4 / 12 | 3 / 12 | +5.4 |
| Pricing transparency | 2.5 / 5 | 5 / 5 | -2.5 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
OTTAVA (J&J MedTech)
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Capital sale. |
PrecisionOS
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Individual, monthly | $199 | n/a | Individual subscription. |
| Individual, yearly | n/a | $1,999 | Individual subscription, billed yearly. |
| Institution | n/a | n/a | Custom quote. No public price. |
Evidence
OTTAVA (J&J MedTech)
FDA decisions
DEN250068 (opens in new tab)De Novo2026-07-21
OTTAVA Robotic Surgical System (applicant Auris Health, Inc.)
PrecisionOS
FDA decisions
K210344 (opens in new tab)510(k)2021-11-10
inVisionOS
Peer-reviewed
3 PubMed records name PrecisionOS.
- Hip Arthroscopy Simulator Training With Immersive Virtual Reality Has Similar Effectiveness to Nonimmersive Virtual Reality. (opens in new tab)
- Virtual Reality-Enabled Resident Education of Lateral-Access Spine Surgery. (opens in new tab)
- Immersive virtual reality in orthopedic surgery as elective subject for medical students : First experiences in curricular teaching. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | OTTAVA (J&J MedTech) | PrecisionOS |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | n/a | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full surgical ai comparison
Surgical video intelligence (Theator), OR analytics (OR Black Box), VR training (Osso VR, FundamentalVR), robotic AI (da Vinci 5 Case Insights). Mostly enterprise capital purchases.